Consensus Biogen Inc.

Stocks

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 02:30:00 11/11/2026 am IST			5-day change	1st Jan Change
253.25 ^USD	-0.64%		+1.74%	+43.90%

09/11	UCB And Biogen Announce Clinical Profile Data For Dapirolizumab Pegol In Systemic Lupus Erythematosus	CI
29/10	Biogen Presents New Data Across Alzheimer?S Disease Portfolio At CTAD 2026	CI

Evolution of the Average Target: Biogen Inc.

Evolution of the Target Price: Biogen Inc.

Changes in Analyst Recommendations: Biogen Inc.

292d80db817c154de6.8XVahzAoGioKi9munob6D8iUELMIME5UyW-ug8mAaeQ.iRsx1XwQbWhL4IPk1siTIvjFcutSACk-gTvc86SxIKO6Bh7RYRBxZkTuug~29a1217ee4f88cb9057f8f7f767d6fd1

Analysts' recommendations: Biogen Inc.

29/10	Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC Says	MT
29/10	Bernstein Adjusts Price Target on Biogen to $278 From $236	MT
29/10	UBS Adjusts Price Target on Biogen to $300 From $270, Keeps Buy Rating	MT
29/10	Argus Research Upgrades Biogen to Buy From Hold, $280 Price Target	MT
29/10	RBC Raises Price Target on Biogen to $272 From $256, Keeps Outperform Rating	MT
29/10	Wedbush Adjusts Price Target on Biogen to $225 From $212, Maintains Neutral Rating	MT
22/10	BofA Securities Adjusts Biogen Price Target to $244 From $219	MT
21/10	TD Cowen Adjusts Price Target on Biogen to $250 From $225	MT
20/10	Wells Fargo Adjusts Price Target on Biogen to $310 From $250	MT
19/10	Wedbush Trims Price Target on Biogen to $212 From $215, Keeps Neutral Rating	MT
13/10	Biogen Shares Rise After JPMorgan Upgrade	MT
12/10	JPMorgan Upgrades Biogen to Overweight From Neutral, $300 Price Target	MT
12/10	BMO Capital Adjusts Price Target on Biogen to $220 From $208	MT
09/10	Jefferies Adjusts Biogen Price Target to $260 From $255	MT
09/10	UBS Adjusts Price Target on Biogen to $270 From $240, Maintains Buy Rating	MT
08/10	RBC Cuts Price Target on Biogen to $256 From $260, Keeps Outperform Rating	MT
03/09	Piper Sander Adjusts Biogen Price Target to $245 From $225, Maintains Overweight Rating	MT
25/08	RBC Capital Adjusts Price Target on Biogen to $260 From $240, Keeps Outperform Rating	MT
25/08	RBC Adjusts Price Target on Biogen to $260 From $240, Maintains Outperform Rating	MT
25/08	RBC Capital Adjusts Price Target on Biogen to $260 From $240	MT
13/08	Wolfe Upgrades Biogen to Outperform From Peer Perform, Price Target is $300	MT
10/08	HSBC Adjusts Price Target on Biogen to $165 From $157, Keeps Reduce Rating	MT
03/08	Mizuho Adjusts Price Target on Biogen to $241 From $221	MT
30/07	BMO Capital Adjusts Price Target on Biogen to $208 From $196, Maintains Market Perform Rating	MT
30/07	TD Cowen Adjusts Price Target on Biogen to $225 From $215, Maintains Buy Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BIOGEN INC.					+5.25%
	ELI LILLY AND COMPANY					+2.94%
	JOHNSON & JOHNSON					-0.96%
	ABBVIE INC.					+5.92%
	ROCHE HOLDING AG					-1.17%
	MERCK & CO., INC.					+8.58%
	NOVARTIS AG					-5.36%
	ASTRAZENECA PLC					+13.76%
	AMGEN INC.					-7.63%
	GILEAD SCIENCES, INC.					+3.22%
	Average					+2.46%
	Weighted average by Cap.					+2.35%